The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail info@hpra.ie


Hexacima



Sanofi Pasteur SAEU/1/13/828/001-007

Main Information

Trade NameHexacima
Active SubstancesHaemophilus influenzae type b capsular polysaccharide
Pertussis toxoid
(polyribosylribitol phosphate) conjugated to tetanous protein
Filamentous haemagglutinin
Type 1 (mahoney)
Diphtheria toxoid
Type 2 (mef-1)
Tetanus toxoid
Type 3 (saukett)
Hepatitis b surface antigen
Dosage FormSuspension for injection
Licence HolderSanofi Pasteur SA
Licence NumberEU/1/13/828/001-007

Group Information

ATC CodeJ07CA Bacterial and viral vaccines, combined
J07CA09 diphtheria-hemophilus influenzae B-pertussis-poliomyelitis-tetanus-hepatitis B

Status

License statusAuthorised
Licence Issued17/04/2013
Legal statusProduct subject to prescription which may not be renewed (A)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of Licence
Marketing StatusUnknown

Documents

Summary of Product CharacteristicsSearch EMA website
Package LeafletSearch EMA website
Public Assessment ReportSearch EMA website
« Back